NEWS RELEASE 06 Jul 2015

NEWS RELEASE 30 Mar 2015

Canadians with Chronic Obstructive Pulmonary disease lack confidence with inhaler: 6 in 10 report challenges

Read more on

Canadians with Chronic Obstructive Pulmonary disease lack confidence with inhaler: 6 in 10 report challenges

NEWS RELEASE 15 Sep 2014

TONADO^™ study finds significant improvement in lung function and quality of life with tiotropium + olodaterol Respimat^{^®*±} Soft Mist Inhaler FDC in Chronic Obstructive Pulmonary Disease

Read more on

TONADO^™ study finds significant improvement in lung function and quality of life with tiotropium + olodaterol Respimat^{^®*±} Soft Mist Inhaler FDC in Chronic Obstructive Pulmonary Disease

NEWS RELEASE 02 Jul 2014

COPD: Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat^{^®*} fixed-dose combination in COPD

Read more on

COPD: Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat^{^®*} fixed-dose combination in COPD

NEWS RELEASE 19 Jun 2014

Study findings show tiotropium Respimat^{^®}* well-tolerated and effective in Japanese patients with symptomatic asthma

Read more on

Study findings show tiotropium Respimat^{^®}* well-tolerated and effective in Japanese patients with symptomatic asthma

NEWS RELEASE 20 May 2014

Study findings show nintedanib* slows progression of Idiopathic Pulmonary Fibrosis (IPF), a debilitating and fatal lung disease

Read more on

Study findings show nintedanib* slows progression of Idiopathic Pulmonary Fibrosis (IPF), a debilitating and fatal lung disease

NEWS RELEASE 09 Sep 2013

Landmark TIOSPIR^TM trial reinforces value of SPIRIVA^{^®} in two formulations as one of the leading maintenance therapies for chronic obstructive pulmonary disease (COPD)

Read more on

Landmark TIOSPIR^TM trial reinforces value of SPIRIVA^{^®} in two formulations as one of the leading maintenance therapies for chronic obstructive pulmonary disease (COPD)

NEWS RELEASE 29 Jan 2013

FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD

Read more on

FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD

Health Canada approves OFEV^™ (nintedanib) for the treatment of idiopathic pulmonary fibrosis

Health Canada approves OFEV^™ (nintedanib) for the treatment of idiopathic pulmonary fibrosis

Canadians with Chronic Obstructive Pulmonary disease lack confidence with inhaler: 6 in 10 report challenges

Canadians with Chronic Obstructive Pulmonary disease lack confidence with inhaler: 6 in 10 report challenges

TONADO^™ study finds significant improvement in lung function and quality of life with tiotropium + olodaterol Respimat^{^®*±} Soft Mist Inhaler FDC in Chronic Obstructive Pulmonary Disease

TONADO^™ study finds significant improvement in lung function and quality of life with tiotropium + olodaterol Respimat^{^®*±} Soft Mist Inhaler FDC in Chronic Obstructive Pulmonary Disease

COPD: Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat^{^®*} fixed-dose combination in COPD

COPD: Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat^{^®*} fixed-dose combination in COPD

Study findings show tiotropium Respimat^{^®}* well-tolerated and effective in Japanese patients with symptomatic asthma

Study findings show tiotropium Respimat^{^®}* well-tolerated and effective in Japanese patients with symptomatic asthma

Study findings show nintedanib* slows progression of Idiopathic Pulmonary Fibrosis (IPF), a debilitating and fatal lung disease

Study findings show nintedanib* slows progression of Idiopathic Pulmonary Fibrosis (IPF), a debilitating and fatal lung disease

Landmark TIOSPIR^TM trial reinforces value of SPIRIVA^{^®} in two formulations as one of the leading maintenance therapies for chronic obstructive pulmonary disease (COPD)

Landmark TIOSPIR^TM trial reinforces value of SPIRIVA^{^®} in two formulations as one of the leading maintenance therapies for chronic obstructive pulmonary disease (COPD)

FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD

FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD

Search form

Health Canada approves OFEV™ (nintedanib) for the treatment of idiopathic pulmonary fibrosis

Health Canada approves OFEV™ (nintedanib) for the treatment of idiopathic pulmonary fibrosis

Canadians with Chronic Obstructive Pulmonary disease lack confidence with inhaler: 6 in 10 report challenges

Canadians with Chronic Obstructive Pulmonary disease lack confidence with inhaler: 6 in 10 report challenges

TONADO™ study finds significant improvement in lung function and quality of life with tiotropium + olodaterol Respimat®*± Soft Mist Inhaler FDC in Chronic Obstructive Pulmonary Disease

TONADO™ study finds significant improvement in lung function and quality of life with tiotropium + olodaterol Respimat®*± Soft Mist Inhaler FDC in Chronic Obstructive Pulmonary Disease

COPD: Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat®* fixed-dose combination in COPD

COPD: Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat®* fixed-dose combination in COPD

Study findings show tiotropium Respimat®* well-tolerated and effective in Japanese patients with symptomatic asthma

Study findings show tiotropium Respimat®* well-tolerated and effective in Japanese patients with symptomatic asthma

Study findings show nintedanib* slows progression of Idiopathic Pulmonary Fibrosis (IPF), a debilitating and fatal lung disease

Study findings show nintedanib* slows progression of Idiopathic Pulmonary Fibrosis (IPF), a debilitating and fatal lung disease

Landmark TIOSPIRTM trial reinforces value of SPIRIVA® in two formulations as one of the leading maintenance therapies for chronic obstructive pulmonary disease (COPD)

Landmark TIOSPIRTM trial reinforces value of SPIRIVA® in two formulations as one of the leading maintenance therapies for chronic obstructive pulmonary disease (COPD)

FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD

FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD

Health Canada approves OFEV^™ (nintedanib) for the treatment of idiopathic pulmonary fibrosis

Health Canada approves OFEV^™ (nintedanib) for the treatment of idiopathic pulmonary fibrosis

TONADO^™ study finds significant improvement in lung function and quality of life with tiotropium + olodaterol Respimat^{^®*±} Soft Mist Inhaler FDC in Chronic Obstructive Pulmonary Disease

TONADO^™ study finds significant improvement in lung function and quality of life with tiotropium + olodaterol Respimat^{^®*±} Soft Mist Inhaler FDC in Chronic Obstructive Pulmonary Disease

COPD: Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat^{^®*} fixed-dose combination in COPD

COPD: Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat^{^®*} fixed-dose combination in COPD

Study findings show tiotropium Respimat^{^®}* well-tolerated and effective in Japanese patients with symptomatic asthma

Study findings show tiotropium Respimat^{^®}* well-tolerated and effective in Japanese patients with symptomatic asthma

Landmark TIOSPIR^TM trial reinforces value of SPIRIVA^{^®} in two formulations as one of the leading maintenance therapies for chronic obstructive pulmonary disease (COPD)

Landmark TIOSPIR^TM trial reinforces value of SPIRIVA^{^®} in two formulations as one of the leading maintenance therapies for chronic obstructive pulmonary disease (COPD)